Kornimate/medical-research-clean huggingface dataset:
cardiovascular and metabolic responses to a mixed meal

Conditions: Insulin Resistance

Summary: the purpose is to determine whether regular endurance exercise and/or body weight influence the way our nervous and vascular systems respond during the metabolism of meals.

to begin to examine this question we recruited healthy endurance-trained (high fit, hf) and normally active (average fit, af) subjects. it is well characterized that chronic endurance training results in enhanced peripheral insulin sensitivity. therefore, our rationale was that inclusion of two healthy subject groups, with distinct differences in insulin sensitivity, would allow us to investigate how enhanced insulin sensitivity influences insulin-mediated changes in central sympathetic outflow. direct measurements of central sympathetic outflow to skeletal muscle (i.e., msna) were recorded, and a mixed meal was used as a physiological method to evoke robust and sustained increases in msna, which have been primarily attributed to insulin. we hypothesized that hf subjects would have a greater msna response, for a given plasma insulin concentration, following consumption of a mixed meal (i.e., greater central insulin sensitivity).

Eligibility criteria:
inclusion criteria: * healthy, not currently taking any medications exclusion criteria: * unhealthy, taking medications

Keywords: insulin resistance
a cross-sectional study to assess the effectiveness and safety of ofatumumab (kesimpta®) in patients with relapsing multiple sclerosis in the spanish clinical practice

Conditions: Relapsing Forms of Multiple Sclerosis

Summary: this is a non-interventional, cross-sectional, multicentric, and nationwide study, based on primary and secondary data collection.

the present study aims to characterize the use of subcutaneous ofatumumab in a real-world setting. specifically, the investigation will assess the effectiveness, safety, and treatment adherence associated with subcutaneous ofatumumab in individuals with relapsing forms of multiple sclerosis (rms) within the spanish healthcare system. the study will use primary and secondary data collection. primary data collection includes information collected using pro, clinical-reported outcomes (clinro), scales or tests and the interview during the study visit. secondary data collection includes existing data from electronic medical records (emr) or paper-based medical records, collected as part of the routine follow-up of patients with rms in the clinical practice. baseline will be defined as the date of ofatumumab initiation.

Eligibility criteria:
inclusion criteria: 1. aged ≥ 18 years. 2. written informed consent. 3. diagnosis of rms per mcdonald criteria (2017). 4. ofatumumab treatment in line with the european kesimpta® summary of product characteristics (smpc; i.e. adult patients with rms with active disease defined by clinical or imaging features) during at least 12 months and patients who discontinued ofatumumab after receiving at least one dose with a minimum monitoring of 12 months. exclusion criteria: 1. currently participating in a clinical trial. 2. not able/unlikely to complete with all study activities according to investigator's criteria. 3. have a contraindication for ofatumumab use, according to the smpc.

Keywords: rms nis spain ofatumumab
resting energy expenditure of the coronavirus (covid19) patient in reanimation context

Conditions: COVID-19; Obesity

Summary: compare the resting energy expenditure of covid-19 patients (obese or non-obese) in intensive care unit with mechanical ventilation to a control group of non-covid-19 intensive care patients.


Eligibility criteria:
inclusion criteria: for the ambulatory obese control group, the inclusion criteria are: * age ≥ 18 years; * patient followed in the nutrition service; * patient who benefited from an indirect calorimetry whatever the indication between 01/01/20 and 31/12/2020; * bmi\> 30. for the covid group and the resuscitation control group, the inclusion criteria are: * age ≥ 18 years; * patient having undergone a resuscitation stay * patient on mechanical ventilation (intubated or tracheotomized) during their stay in intensive care; * patient having benefited from an indirect calorimetry upon arrival in intensive care; only for the covid group: * patient hospitalized in intensive care for covid 19 infection diagnosed by a positive pcr via nasopharyngeal sampling or endotracheal aspiration. * patient who has not yet carried out his post-resuscitation visit; only for the resuscitation control group: - patient hospitalized in intensive care for an indication other than an infectious cause. exclusion criteria: non-inclusion criteria for the ambulatory obese control group: * person deprived of liberty; * person subject to legal protection measures; * patient's opposition to participate in research. the non-inclusion criteria for the covid group and the resuscitation control group: * for patients intubated during the resuscitation stay fi02\> 70% which does not allow a correct interpretation of the calorimetry; * pregnancy ; * person deprived of liberty; * person subject to legal protection measures; * opposition of the patient or the person of trust to participate in the research. only for the covid group: * contraindication to indirect calorimetry (claustrophobia for post-resuscitation patients where calorimetry is performed with a mask); * contraindication to bioimpedancemetry (electronic implants, limb amputation, weight \ 300kg);

Keywords: resting energy expenditure artificial nutrition
effect low pressure pneumoperitoneum and pulmonary recruitment on postoperative pain

Conditions: Pneumoperitoneum; Recruitment; Postoperative Pain

Summary: the investigators want to test the hypothesis that the addition of a recruitment manoeuvre to a low pressure pneumoperitoneum will lead to an additional reduction in postoperative pain. therefore the investigators will conduct a prospective randomized controlled, single blind trial.

two groups: 1. a cholecystectomy at a low pressure pneumoperitoneum (8-10 mmhg) 2. a cholecystectomy at a lowpressure pneumoperitoneum (8-10mmhg) and at the end a pulmonary recruitment manoeuvre (5 sec at max 40 cmh2o).

Eligibility criteria:
inclusion criteria: * asa i and ii exclusion criteria: * refusal to give consent * cholecystitis * bmi above 35 * intolerance to one of the pain medication * pregnancy
vibrotactile coordinated reset for parkinson's patients of a more variable population

Conditions: Parkinson Disease

Summary: the purpose of our study is to evaluate vibrotactile coordinated reset stimulation (vcr) and its effects on parkinson's symptoms of a more variable population. vcr will be administered with a device called the stanford glove. vcr is expected to provide patients with a non-invasive alternative to the most widely used treatments such as levodopa and or deep brain stimulation. patients will be followed for two years.


Eligibility criteria:
inclusion criteria: 1. age at the time of enrollment: 35 - 92 years 2. idiopathic parkinson's symptoms between hoehn and yahr stages 2 to 3. fluent in english 4. comfortable with technology; can use a computer, check email, and access the internet; can initiate and engage in a virtual meeting for training and monitoring purposes. 5. feels comfortable going off pd related medication during in person study visits 6. lives in the united states exclusion criteria: 1. any significant neuro-psychiatric problems, including acute confusional state, ongoing psychosis, or suicidal tendencies 2. any current drug or alcohol abuse. 3. participation in another drug, device, or biologics trial concurrently or within the preceding 30 days. any other trial participation should be approved by the principal investigators. 4. pregnancy, breast-feeding or wanting to become pregnant 5. craniotomy 6. brain surgery 7. patient is unable to communicate properly with staff (i.e., severe speech problems) 8. excessive drooling 9. patient is taking a medication that may cause significant withdrawal effects
positive psychology for mood disorders

Conditions: Bipolar Disorder; Depression

Summary: the investigators are doing this study to see if "positive psychology" can help adults with depression or bipolar disorder. positive psychology involves exercises-short tasks-that try to increase good feelings and emotions, like optimism, happiness, personal strengths, and well-being. positive psychology exercises might include imagining a bright future, being grateful for good events, forgiving others, and doing kind acts for others. the investigators want to see if practicing positive psychology exercises after leaving the hospital can increase feelings of hope, optimism, and positive thinking. the investigators are asking you to take part in this research study because you are in the hospital for depression or bipolar disorder. this research study will compare "positive psychology exercises" to "control condition exercises." during the study, you may take part in control condition exercises instead of positive psychology exercises.


Eligibility criteria:
inclusion criteria: * patient admitted to massachusetts general hospital inpatient psychiatric unit * age 18 and older * able to read and write in english * admission diagnosis of major depressive disorder or bipolar affective disorder (current depressive episode), confirmed using the mini international neuropsychiatric interview and inpatient chart review exclusion criteria: * psychotic symptoms, as assessed using the mini international neuropsychiatric interview and inpatient chart review * cognitive disorder, assessed using a six-item cognitive screen developed for research * primary admission diagnosis of substance use disorder

Keywords: bipolar disorder depression positive psychology
evaluation of nv701 (pilocarpine 1.25%) compared with vuity (pilocarpine 1.25%) on pupil size in subjects with presbyopia

Conditions: Pupil Constriction

Summary: randomized contralateral eye study to evaluate the effect of one-time dosing of nv701 versus commercially available 1.25% pilocarpine solution on pupil size.


Eligibility criteria:
inclusion criteria: * age 40-55 years with presbyopia * able to understand and willing to sign the informed consent for the study * resting mesopic pupil diameter of \>4 mm in both eyes * change in mesopic pupil diameter of \>1 mm after 1 hour in response to pilocarpine 1.25% in both eyes * willing to abstain from contact lens use for 7 days before the study visit * women of childbearing age must have a negative urine pregnancy test at the screening visit and be willing to use a reliable method of birth control during the study exclusion criteria: * anisocoria \>1 mm in photopic or mesopic conditions * high myopia (-6.00 diopters or greater) * any iris abnormality making it difficult to judge pupil diameter as determined by the principal investigator * known allergy to any of the study products or medications * concurrent use of any topical prescription ophthalmic products * history of uveitis or intraocular inflammation * inability to complete any of the study procedures * history of ocular surgery other than lasik or prk * history of retinal tear or retinal detachment * presence of retinal lattice degeneration, operculated hole, or other retinal pathology on screening exam. * history of punctal plugs or punctal cautery in one or both eyes * history of nasolacrimal duct surgery in one or both eyes * history of blepharoplasty or ptosis surgery in one or both eyes * history of glaucoma, glaucoma suspect or ocular hypertension diagnosis * history of acute angle closure or laser peripheral iridotomy * history of moderate or severe dry eye disease * females who are pregnant, nursing, or planning a pregnancy during the study * females of childbearing potential and males with partners of childbearing potential who do not agree to use reliable contraception during the study * uncontrolled systemic disease
safety and efficacy study of gatifloxacin compared with ciprofloxacin in patients with acute bacterial corneal ulcers

Conditions: Acute Bacterial Corneal Ulcers; Bacterial Keratitis

Summary: this study evaluates the safety and efficacy of gatifloxacin 0.3% ophthalmic solution compared with ciprofloxacin 0.3% ophthalmic solution in patients with acute bacterial corneal ulcers


Eligibility criteria:
inclusion criteria: * clinical diagnosis in one eye only of an acute bacterial corneal ulcer (\>1mm) exclusion criteria: * corneal ulcer that in the opinion of the investigator had to be treated with fortified antibiotics, or multiple antibiotics, or anti-infectives other than study medication
pivotal response treatment for children with autism spectrum disorders

Conditions: Autism Spectrum Disorders

Summary: the purpose of this study is to evaluate the application of an evidence-based, manualized treatment for children with autism spectrum disorder (asd) (pivotal response treatment, prt) to children ages four through six years of age with asd. specifically, children will be randomly assigned to receive either (1) 10 hours per week of intervention services, including two hours per week of parent education, and eight hours per week of direct clinician-delivered services, or (2) a treatment as usual control. intervention will focus on enhancing the following developmental skills: expressive and receptive language, play, and social interaction. outcome measures will address changes in the aforementioned domains during structured observation and standardized assessment.


Eligibility criteria:
inclusion criteria: * inclusion criteria: participants will: 1. fit the age requirement: age 4-35 2. have been diagnosed previously with an asd and meet criteria for asd when characterized by research team. 3. be in good medical health 4. be cooperative with testing 5. english is a language spoken in the family 6. successfully complete an fmri and eeg scan 7. full-scale iq\>50 exclusion criteria: * exclusion criteria: participants may not have: 1. any metal or electromagnetic implants, including: 1. cardiac pacemaker 2. defibrillator 3. artificial heart valve 4. aneurysm clip 5. cochlear implants 6. shrapnel 7. neurostimulators 8. history of metal fragments in eyes or skin 2. significant hearing loss or other severe sensory impairment 3. a fragile health status. 4. current use of prescription medications that may affect cognitive processes under study. 5. a history of significant head trauma or serious brain or psychiatric illness

Keywords: asd
coronary and heart effects of early treatment in familial hypercholesterolemia

Conditions: Familial Hypercholesterolemia

Summary: this study evaluates plaque burden and characteristics in early-treated fh patients compared to late-treated fh patients and healthy individuals.


Eligibility criteria:
inclusion criteria: * diagnosed with heterozygous familial hypercholesterolemia or non fh-control * adult patients between 25 and 55 years old. exclusion criteria: * renal insufficiency, defined as egfr \< 30 ml/min * atrial fibrillation * any other treatment or clinically relevant condition that could interfere with the conduct or interpretation of the study in the opinion of the investigator * inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
effects of berry peel intake on glucose metabolism in healthy subjects

Conditions: Healthy

Summary: the main objective of this study is to investigate the effect of a 4-weeks intake of berry peel powder on fasting and postprandial glucose metabolism and inflammatory markers. the berry peel product will be compared with a placebo in a single-blind, cross-over design. furthermore, inflammation-related peripheral blood mononuclear cells (pbmcs) genes expression, appetite and cognitive performance will be included as a pilot study. investigators hypothesize that long-term consumption of polyphenols and fibres of berry peel will exhibit both direct and indirect actions in healthy overweight subjects by improvement of glucose-associated markers as well as ameliorating inflammation. moreover, above metabolic markers will correlated with improvements in inflammation-related pbmcs genes expression, subjective appetite and cognitive performance after long-term consumption of berry peel as a source of polyphenols.


Eligibility criteria:
inclusion criteria: * healthy males and females * signed informed consent * bmi 25-30 kg/m2 * must be able to accept plant-based foods/drinks exclusion criteria: * below 18 years or above 40 years * smoking or using snuff * vegetarian or vegan * stressed by venous blood sampling or previous experience of being difficult canulation

Keywords: berry inflammation cognition polyphenols appetite glucose metabolism
rifaximin ssd in dementia trial

Conditions: Dementia Alzheimer Type; Dementia Associated With Cerebrovascular Disease

Summary: using a new formulation of rifaximin, a non-absorbable antibiotic, to test if it can affect microbes in the gut of patients with dementia favorably.

hypothesis: rifaximin ssd therapy is safe and well tolerated in patients with ad and vad with beneficial changes in systemic inflammation and systemic biomarkers of dementia due to improvement in microbiota function compared to placebo-related changes in a single-blind, placebo-controlled phase 1b/2a trial . overall objective: in a single blind placebo-controlled trial in patients with alzheimer's or vascular dementia, to determine the effect of rifaximin ssd compared to placebo on gut microbial structure and function, cognitive and daily function, and caregiver burden.

Eligibility criteria:
inclusion criteria: * probable alzheimer's disease (ad) or vascular dementia (vad) mild or moderate based on clinical dementia rating scale. * males and females age ≥ 65 years * community living with availability of caregiver to accompany participant to study visits and to participate in the study. * able to consent or legal guardian who can consent (with participant assent). * legally authorized representative (lar) and caregiver for the study is the same individual. * fluency (both participant and caregiver) in written and spoken english to participate in study visits. exclusion criteria: * dementia not due to ad or vad * clinically significant agitation or aggression (requiring treatment with antipsychotic medication) * delusions and/or hallucinations * severe psychopathology including major depression * unstable, severe, or poorly controlled medical conditions evident from physical examination or clinical history * visual and/or hearing disorder that prevents completion of neuropsychologic evaluations. * diarrhea * hypersensitivity to rifaximin, components of rifaximin, * and any rifamycin antimicrobial agent * antibiotic use in the prior 6 months * taking medications that interact with rifaximin. p-glycoprotein (p-gp) inhibitor treatment is permitted as long as the use of p-gp inhibitors is discussed with the investigator. * history of alcohol and/or drug abuse * participation in another investigational drug trial in the last 30 days

Keywords: dementia rifaximin gut-brain alzheimer&#39;s vascular dementia
the osteosarcoma biobank in peking university people's hospital

Conditions: Osteosarcoma

Summary: osteosarcoma is very rare bone tumor. the investigator set up the biobank to ensure the patients has the chance to participate in future research

samples of blood and other stored material such as slides,frozen tissues and so on . questionnaire information, including health history, growth and development, physical activity and family medical history information.

Eligibility criteria:
inclusion criteria: proband inclusion criteria: a diagnosis or suspected diagnosis of osteosarcoma exclusion criteria: non-asian pulmonary metastasis

Keywords: bone tumor osteosarcoma
frank score and coronary artery disease

Conditions: Coronary Artery Disease

Summary: patients with coronary artery disease (cad) were enrolled. cad was diagnosed by coronary angiography which also resulted syntax score. images of left and right ears were captured by a digital camera. frank score of each patients was calculated based on characteristics and numbers of wrinkles of the earlobes. statistic analysis were carried out to analyze the correlation between frank score and syntax score.


Eligibility criteria:
inclusion criteria: * diagnosis coronary artery disease by coronary angiography exclusion criteria: * diagnosis of malignant tumor * positive heart transplant history * positive cabg history * positive pci history * pregnant and lactating women * diagnosis of chronic kidney disease * any external ear trauma or disease history

Keywords: syntax score frank sign coronary angiography
a clinical trial of tqb3909 tablets in combination with azacitidine for the treatment of myeloid malignancies

Conditions: Myeloid Malignancy

Summary: this is an open, multi-center clinical study designed to evaluate the safety, tolerability and efficacy of tqb3909 tablets in combination with azacitidine in subjects with myeloid malignancies.


Eligibility criteria:
inclusion criteria: * voluntary and signed informed consent, good compliance * age: ≥18 years old (at the time of signing the informed consent); expected survival time greater than 3 months. * diagnosis of one of the following diseases: 1. acute myeloid leukemia (aml): 2. myelodysplastic syndromes (mds) 3. major organ functions are normal. 4. fertile male and female subjects agree to use contraception during the study and for 6 months after the study ends. exclusion criteria: * comorbidities and medical history: 1. diagnosis of or current concomitant malignancy within 3 years prior to the first dose; 2. presence of multiple factors affecting oral drug intake and/or absorption; 3. major surgical procedures or significant traumatic injuries within 28 days prior to the first dose; 4. history of arterial/venous thrombotic events within 6 months prior to the first dose; 5. history of psychiatric drug abuse that cannot be discontinued, or psychiatric disorders; 6. presence of any severe and/or uncontrolled disease in the subject. * tumor-related symptoms and treatment: 1. diagnosis of acute promyelocytic leukemia (apl), myelodysplastic syndromes/myeloproliferative neoplasms (mds/mpn); 2. presence of leukemia central nervous system (cns) involvement or high suspicion of cns involvement but unable to confirm; 3. subjects with extramedullary disease only in aml; 4. presence of life-threatening severe leukemia-related complications; * study treatment-related: 1. received live vaccines within 4 weeks prior to the first dose, or planned to receive live vaccines during the study period; 2. participated in other clinical trials involving anti-tumor drugs within 4 weeks prior to the first dose.